Efficacy of twice-daily levobunolol in the treatment of elevated intraocular pressure

The efficacy of twice-daily treatment with 0.5% levobunolol hdyrochloride was compared with that of 0.5% timolol maleate in 27 patients with open-angle glaucoma or ocular hypertension in a double-blined randomized trial. At all follow-up visits the patients in both groups had significantly decreased intraocular pressure (p < 0.05); there was no significant difference between the groups. Levobunolol produced significant decreases in mean heart rate (p < 0.05). One patient with an undisclosed history of childhood asthma experienced bronchospasm related to an acute upper respiratory tract infection while receiving levobunolol. Neither drug caused any significant ocular problems. The results show a clear ocular hypotensive effect with twice-daily 0.5% levobunolol.